Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic by A.C. Pineda-Pe&#241 et al.
Trends and Predictors of Transmitted Drug Resistance
(TDR) and Clusters with TDR in a Local Belgian HIV-1
Epidemic
Andrea-Clemencia Pineda-Pen˜a1,2, Yoeri Schrooten1,3, Lore Vinken1, Fossie Ferreira1, Guangdi Li1,
Nı´dia Sequeira Trova˜o1, Ricardo Khouri1, Inge Derdelinckx4,5, Paul De Munter4,5, Claudia Ku¨cherer6,
Leondios G. Kostrikis7, Claus Nielsen8, Kirsi Littsola9, Annemarie Wensing10, Maja Stanojevic11,
Roger Paredes12, Claudia Balotta13, Jan Albert14,15, Charles Boucher16, Arley Gomez-Lopez2,
Eric Van Wijngaerden4,5, Marc Van Ranst1,3, Jurgen Vercauteren1, Anne-Mieke Vandamme1,17,
Kristel Van Laethem1,3*
1 Clinical and Epidemiological Virology, Rega Institute for Medical Research, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium, 2 Clinical and
Molecular Infectious Diseases Group, Faculty of Sciences and Mathematics, Universidad del Rosario, Bogota´, Colombia, 3 AIDS Reference Laboratory, University Hospitals
Leuven, Leuven, Belgium, 4 Clinical Infectious and Inflammatory Disorders, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium, 5 Internal
Medicine, University Hospitals Leuven, Leuven, Belgium, 6 Robert Koch-Institut, Berlin, Germany, 7 University of Cyprus, Nicosia, Cyprus, 8 Statens Serum Institut,
Copenhagen, Denmark, 9 National Institute of health and welfare, Helsinki, Finland, 10 Department of Virology, University Medical Center Utrecht, The Netherlands,
11 University of Belgrade, Faculty of Medicine, Belgrade, Serbia, 12 IrsiCaixa Foundation, Badalona, Spain, 13 Luigi Sacco University Hospital, Milan, Italy, 14 Department
of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden, 15 Department of Clinical Microbiology, Karolinska University Hospital, Stockholm,
Sweden, 16 Erasmus MC, University Medical Center, Rotterdam, The Netherlands, 17 Centro de Mala´ria e outras Doenc¸as Tropicais and Unidade de Microbiologia, Instituto
de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa, Portugal
Abstract
We aimed to study epidemic trends and predictors for transmitted drug resistance (TDR) in our region, its clinical impact
and its association with transmission clusters. We included 778 patients from the AIDS Reference Center in Leuven (Belgium)
diagnosed from 1998 to 2012. Resistance testing was performed using population-based sequencing and TDR was
estimated using the WHO-2009 surveillance list. Phylogenetic analysis was performed using maximum likelihood and
Bayesian techniques. The cohort was predominantly Belgian (58.4%), men who have sex with men (MSM) (42.8%), and
chronically infected (86.5%). The overall TDR prevalence was 9.6% (95% confidence interval (CI): 7.7–11.9), 6.5% (CI: 5.0–8.5)
for nucleoside reverse transcriptase inhibitors (NRTI), 2.2% (CI: 1.4–3.5) for non-NRTI (NNRTI), and 2.2% (CI: 1.4–3.5) for
protease inhibitors. A significant parabolic trend of NNRTI-TDR was found (p = 0.019). Factors significantly associated with
TDR in univariate analysis were male gender, Belgian origin, MSM, recent infection, transmission clusters and subtype B,
while multivariate and Bayesian network analysis singled out subtype B as the most predictive factor of TDR. Subtype B was
related with transmission clusters with TDR that included 42.6% of the TDR patients. Thanks to resistance testing, 83% of the
patients with TDR who started therapy had undetectable viral load whereas half of the patients would likely have received a
suboptimal therapy without this test. In conclusion, TDR remained stable and a NNRTI up-and-down trend was observed.
While the presence of clusters with TDR is worrying, we could not identify an independent, non-sequence based predictor
for TDR or transmission clusters with TDR that could help with guidelines or public health measures.
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Introduction
In recent years, the number of newly diagnosed HIV-1 patients
increased in Belgium [1] with a rate of 10.7 per 100,000
population in 2011, one of the highest rates in Europe [2].
Studies carried out in Europe and America highlighted the
important role of transmission networks in the spread of
transmitted drug resistance (TDR) [3–7]. TDR is a clinical and
public health issue because it can compromise the response to
antiretroviral therapy (ART) at the individual and population level
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[8]. Three nationwide studies were performed previously in
Belgium and reported a TDR prevalence of 29% (67/231; 95%
CI: 23.5–35.2) between 1995 and 1998 [9], 7.2% (6/83; 95% CI:
3.4–14.9) in 2000 [10] and 9.5% (27/285, 95% CI: 6.6–13.4)
between 2003 and 2006 [11]. However, due to differences in
methodology and the lack of a recent study, no up-to-date
information is yet available on TDR trends in Belgium.
Nevertheless, recent reports revealed the rapid onward transmis-
sion of an HIV-1 strain with K103N mutation [12] and the
involvement of transmission clusters (TCs) in approximately half of
patients with TDR [4] in a local HIV epidemic in Belgium.
Because other studies consistently showed regional differences
between the drivers of the HIV-1 epidemic [13,14], this study
aimed to characterize the temporal trend in TDR, the factors
associated with TDR including TCs and the clinical impact of
TDR for a period of 15 years in a regional epidemic, serviced by
the Leuven University Hospitals. The data included socio-
demographic, clinical and virological variables.
Materials and Methods
Ethics Statement
The research was conducted according to the Declaration of
Helsinki. Only patients for whom written informed consent was
obtained were included in this study, except patients enrolled in
care after 2009. In 2009, UZ Leuven implemented a generic ‘‘opt
out’’ system. Patients, who logged an objection to use their medical
data for research purposes, were not included in this study. The
protocol and this consent procedure were approved by the Ethical
Committee UZ Leuven (reference ML-8627, approval
B322201316521 S52637).
Study Population
We analysed data from the cohort of the AIDS Reference
Centre (ARC) in Leuven, the capital of the province of Flemish
Brabant (Belgium). The ARC in Leuven has been collecting
information since 1997 on treated HIV-1 patients and since 1999,
also for naive HIV-1 patients, including epidemiological, clinical
and virological data, related with the routine patient healthcare
services. The prospective clinical use of baseline genotypic drug
resistance testing was implemented in 1999 and stored plasma
samples from before 1999 were available to retrospectively
perform drug resistance testing upon clinician’s request. Therefore
HIV-1 sequences for drug naive patients were either prospectively
or retrospectively obtained from a sample taken at diagnosis,
except for 135 patients for whom a later pre-therapy sample was
used. The inclusion criteria for the analysis of TDR in the present
study were newly HIV-1 diagnosed between January 1998 and
December 2012, availability of a nucleotide sequence before
antiviral therapy initiation and age older than 18 years, and this
cohort was called the Leuven newly-diagnosed (ND) cohort for the
purpose of this study. The only exclusion criterion used was
documented vertical transmission. Recent infections were defined
using clinical and laboratory information such as p24 ELISA,
HIV-specific antibody ELISA, and Inno-Lia profile. Patients with
the following criteria were classified as recently infected: Fiebig
stages I-V [15] or no more than 6 months difference between the
last seronegative and first seropositive HIV-1 test [11], CD4 count
.200 cells/ml and absence of AIDS-defining conditions [16].
Drug Resistance Testing
Drug resistance testing was performed using population-based
Sanger sequencing of the pol gene fragment encoding protease
(PR) (amino acids 1 to 99) and 59-prime end of reverse
transcriptase (RT) (amino acids 1 to 320). Sequences were
obtained using the ViroSeq HIV-1 Genotyping System version 2
(Celera Diagnostics, Alameda, CA) or with an in-house method
upon failure of the commercial test [17]. Sequences with
associated information are available through Euresist (http://
www.euresist.org).
TDR mutations were defined according to the 2009 list of
surveillance drug resistance mutations from the World Health
Organization [18]. Therefore, the nucleotide sequences were
submitted to the Calibrated Population Resistance tool version 6.0
(http://cpr.stanford.edu/cpr.cgi). The clinical impact of genotypic
drug resistance on first line therapy was evaluated using Rega
algorithm [19] version 9.1.0 (available at http://rega.kuleuven.
be/cev/avd/software/rega-algorithm).
HIV-1 Subtyping
HIV-1 subtypes and circulating recombinant forms (CRF) were
determined using two HIV-1 subtyping tools, namely Rega version
3 (http://www.bioafrica.net/typing-v3/hiv) and COMET version
0.3 (http://comet.retrovirology.lu/) [20–22]. Sequences with
discordant results were analyzed using manual phylogenetic
analysis as was explained previously [22]. Briefly, maximum
likelihood (ML) phylogenetic trees under the GTR+C nucleotide
substitution model were built with RAxML [23] and recombina-
tion was verified using SimPlot [24].
Transmission Cluster Analysis
To investigate the factors associated with TDR and onward
transmission of TDR, cluster analyses were performed on the
Leuven ND cohort and four additional datasets as controls: (i) all
other pol sequences from the ARC in Leuven, including treated
HIV-1 patients, HIV-1 patients younger than 18 years old and
HIV-1 patients with vertical mode of transmission, (ii) HIV-1 pol
sequences obtained with the search term ‘‘Belgium’’ as sampling
country in the Los Alamos HIV sequence database (retrieved from
http://www.hiv.lanl.gov date in April 2013), (iii) HIV-1 pol
sequences from the collaborative study SPREAD that enrolled
patients with newly diagnosed HIV-1 infection from 22 European
countries including Belgium between 2002 and 2008 (see details of
the study in [25,26]), and (iv) the 30 most similar sequences to the
Leuven ND cohort (retrieved by Basic Local Alignment Search
Tool (BLAST) from http://blast.ncbi.nlm.nih.gov/Blast.cgi). The
quality control of the sequences was performed using the tool
available at http://www.hiv.lanl.gov/content/sequence/QC/ and
the criteria previously described [27]. Separate datasets were
constructed according to subtype. As an out-group, two or three
reference sequences of subtype D or B (retrieved from http://
www.hiv.lanl.gov) were included for B and non-B subtypes,
respectively. Sequences were aligned with Muscle as accessory
application in the program Mega version 5 [28,29]. Duplicates
were removed and the positions encoding surveillance drug
resistance mutations were excluded [18], which resulted in an
average final length of 950 nucleotides. In the resulting dataset, we
had 755 sequences for subtype A, 4225 for subtype B, 1036 for
subtype C, 202 for subtype F, 665 for subtype G, 440 for
CRF01_AE and 677 for CFR02_AG to perform phylogenetic
analyses on. Subtypes with frequencies less than 1% were not
included in TCs analyses.
A ML tree was inferred with the nucleotide substitution GTR+
C model and 1000 bootstrap replicates in RAxML [23]. TCs,
including pairs (two individuals) and larger clusters ($3 individ-
uals), were identified by using Cluster Picker (retrieved from
http://hiv.bio.ed.ac.uk/software.html) [30] with a genetic distance
less or equal than 0.06 substitutions per site and bootstrap support
Transmitted Drug Resistance in a Belgian Regional Epidemic
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$98%. A sensitivity analysis was performed to evaluate the effect
of other genetic distances (0.015, 0.030 and 0.045) [31–34].
The robustness of the identified TCs was evaluated using
Bayesian phylogenetic analysis. TCs and the closest control
sequences together with two reference sequences as an out-group
were selected and trees were constructed with BEAST v1.7.5 [35]
using a lognormal relaxed molecular clock with the SRD06 model
of nucleotide substitutions [36] and a Bayesian skyline coalescent
prior. The analyses were run in triplicate for 100 million states and
trees were sampled every 10000th states. Maximum clade
credibility trees (MCC) were summarized using TreeAnnotator
after 10% of the burn-in was discarded and visualized with
FigTree v.1.4 (available at http://tree.bio.ed.ac.uk). The TCs with
a Bayesian posterior probability of 1 were considered robust
enough and included in the analysis.
Finally, we defined TCs with TDR as any pair or cluster with
more than 3 patients that included at least one patient with TDR
from the Leuven ND cohort. The TCs with TDR with more than
3 individuals with similar TDR mutation profile can be suggestive
of onward transmission of TDR, they are specifically indicated as
TCs with TDR-OT.
Statistical Analysis
Prevalence of TDR and TDR mutations were calculated with a
95% Wilson score confidence interval (95% CI) on the basis of a
binomial distribution, and their trend was calculated by logistic
regression analysis. Socio-demographic, virological and clinical
variables that were significantly associated with TDR or with TCs
with TDR were evaluated in the Leuven cohort. Analyses were
performed on patients involved in TCs from the Leuven ND
cohort, and from Leuven ND cohort with the other four control
datasets. Categorical data were compared using the Chi-square
test, the Fisher’s exact test or regression techniques as appropriate.
The t-test or Mann–Whitney U test was used to compare
continuous data. The statistical significance was set at p,0.05
two-sided. All data were analysed using the statistical R software
version 2.13.1.
Bayesian Network Learning
Those factors that were found to be significantly associated with
TDR or TCs with TDR in univariate analysis were included in a
Bayesian network analysis. This is a probabilistic model that
describes statistical conditional dependencies between multiple
variables and was performed using the B-course software adapted
by Deforche et al [37]. In this analysis, the arcs were scored based
on the stability of the conditional dependency assessed with 100
non-parametric bootstrap replicates. The arcs with bootstrap over
75% were considered and depicted in the consensus network.
Results
General Characteristics Of The Study Population
778 of the 795 patients who were newly diagnosed with an HIV-
1 infection and who received a baseline genotypic drug resistance
test between January 1998 and December 2012 at University
Hospitals Leuven were included in the analysis, they are referred
to as the Leuven ND cohort. Two patients were excluded because
their risk group was vertical transmission. For 15 patients, the
baseline nucleotide sequence did not fulfill the preset quality
criteria: 14 sequences did not have the gene fragments encoding
PR or RT, and one sequence was excluded due to the presence of
more than four stop codons and indels. The included HIV-1
patients were between 18 and 78 years old and were predomi-
nantly male (73.7%), of Belgian origin (58.4%), chronically
infected (86.5%) with CDC stage 1 or 2 (67.0%) (Table 1).
Patients originating from Belgium were more frequently diagnosed
with a recent infection and displayed higher viral loads and CD4
counts (p,0.001). Of all included HIV-1 patients originated from
Belgium, 66.7% reported men who have sex with men (MSM) or
bisexual contacts as risk factor, whereas 22.5% reported hetero-
sexual contacts. In contrast, HIV-1 patients originating from Sub-
Saharan countries reported infection through heterosexual con-
tacts predominantly (79.3%). HIV-1 patients from Sub-Saharan
countries were more likely to be co-infected with hepatitis B than
patients from Belgium (60.9% vs. 34.8%; OR: 4.49, 95% CI 1.75–
12.15, p,0.001). There were 36 HIV-1 therapy-naive patients
who did not receive a baseline drug resistance test in this period.
This group included more patients of non-Belgian origin (75.0%)
and with CD4 count above 500 cells/mL (42.4%, 14/33).
The demographic characteristics of the Leuven ND cohort were
compared to the general HIV-1 population in Belgium, as
reported by the Belgian Scientific Institute of Public Health
(information until 2011) (available at www.wiv-isp.be) [1]. The
Leuven ND cohort contained more men (73.5% vs. 61.0%, p,
0.0002) and Belgians (58.4% vs. 40.6%, p,0.0002) and more
MSM (55.9% vs. 42.5%, p,0.0002). National data only covered
gender and country of origin from 1998 to 2011, and transmission
risk from 2005 to 2011.
Subtypes
52.2% of the HIV-1 patients were infected with subtype B,
followed by CRF02_AG (11.2%), subtype C (10.3%), subtype A
(7.7%), CRF01_AE (6.6%), subtype F (2.8%), subtype G (2.1%)
and unique recombinant forms (4.8%). Subtypes D, H, J,
CRF09_cpx, CRF12_BF, CRF13_cpx, CRF14_BG, CRF18_cpx,
CRF22_01A1, CRF37_cpx, and CRF45_cpx were each found in
less than 1%. Of the patients with a subtype B infection, 81.0%
were of Belgian origin and 71.9% were MSM. Whereas in patients
with non-B infections, 33.6% and 51.6% had a Belgian or sub-
Saharan origin, respectively, and 69.9% were infected through
heterosexual contacts, followed by bisexual/MSM risk factor
(13.2%).
Levels And Trends Of Transmitted Drug Resistance
The overall TDR prevalence was 9.6% (75/778; 95% CI 7.7–
11.9). The prevalence of TDR against nucleoside RT inhibitors
(NRTI) was 6.5% (51/778; 95% CI 5.0–8.5), against non-NRTI
(NNRTI) was 2.2% (17/778; 95% CI 1.4–3.5), and against
protease inhibitors (PI) 2.2% (17/778; 95% CI 1.4–3.5). In
recently infected individuals, the prevalence of overall TDR was
16.2% (17/105; 95% CI 10.4–24.4), significantly higher than in
patients with chronic or unknown duration of infection (8.6%, 58/
673; 95% CI 6.7–11.0). The prevalence of TDR by drug class also
varied in recently infected individuals. The prevalence of TDR
against NRTI was 12.4% (13/105; 95%CI 7.4–20.0), against
NNRTI 1.9% (2/105; 95%CI 0.5–6.7), and against PI 6.7% (7/
105; 95%CI 3.3–13.1). Dual resistance was detected in 10 patients
(1.3%): 3 displayed TDR against NRTI and NNRTI, 6 against
NRTI and PI and one against NNRTI and PI. The latter patient
with NNRTI and PI resistance and 4 out of 6 individuals with
NRTI and PI resistance were recently infected patients (5/105;
4.8%). No triple class resistance was observed.
The majority of the 75 TDR patients displayed one single
mutation (70.7%), mainly related to NRTI (58.5%) and NNRTI
resistance (24.5%). The revertants at RT position 215 were the
most prevalent (44%), followed by M41L (18.7%), K103N
(17.3%), L210W (10.7%), K219Q (10.7%), D67N (6.7%),
K219R (5.3%), G190A (4.0%), M184V (2.7%), L74V (1.3%),
Transmitted Drug Resistance in a Belgian Regional Epidemic
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Y115F (1.3%) and Y181C (1.3%). Within PR, I54VT (10.7%) was
the most frequent mutation followed by M46IL (9.3%), N88D
(6.7%), V82TS (2.7%), L24I (1.3%), I54T (1.3%) and I85V
(1.3%). As the inclusion of PR position 46 within the TDR
mutation list has been debated due to its polymorphic nature [38],
TDR was recalculated excluding this position. This resulted in an
overall TDR of 8.9% (69/778; 95% CI 7.0–11.0) and a PI-TDR
of 1.4% (11/778; 95% CI 0.8–2.5).
No significant time trends were found in the overall TDR
prevalence, nor in transmitted NRTI and PI resistance (see
Figure 1A). A parabolic trend was observed for NNRTI-TDR
(p= 0.019) with a peak in 2008. That corresponded with a peak in
occurrence of K103N (p= 0.026), the only mutation with a
temporal trend. Surprisingly, the parabolic temporal NNRTI-
TDR trend was not observed in the recently infected individuals.
Instead, a stable temporal trend was observed for overall TDR and
individual drug classes in this subset of patients. When the analysis
was performed according to region of origin, a significant
parabolic trend of NNRTI resistance was only found in patients
originating from Belgium (p= 0.039).
Factors Associated With Transmitted Drug Resistance
Univariate analysis was performed to identify predictors of
TDR (Table 1), which were male gender (odds ratio (OR) 3.25,
95% CI 1.52–7.99, p,0.001), Belgian origin (OR 2.09, 95% CI
1.20–3.77, p= 0.006), MSM transmission (OR 2.44, 95% CI
1.46–4.15, p,0.001), recent infection (OR 2.04, 95% CI 1.06–
3.75, p= 0.02), being part of TCs (OR 1.95, 95% CI 1.15–3.25,
p = 0.010) and infected with subtype B virus (OR 3.77, 95% CI
2.09–7.17, p,0.001). Only the latter remained a significant factor
(OR 3.04, 95% CI 1.45–6.35, p = 0.003) in multivariate analysis.
Since these types of analyses do not display possible interdepen-
dencies of the variables and subtype B was most frequently found
in MSM originating in Belgium (p,0.001), we evaluated the
interdependencies of the variables with a Bayesian network
approach. TDR was directly associated only with subtype B, but
this subtype was strongly associated with MSM (100% bootstrap
support) and with Belgian origin (97% bootstrap support), and to a
lesser extent to being part of TCs (78% bootstrap support) (See
Figure 1B). To verify whether we could find an important
predictor of TDR that could be used in guidelines to target a
subpopulation of newly diagnosed for preferential drug resistance
testing, we repeated the analysis excluding any information that
results from the genotype itself. When subtype B was thus excluded
from the analysis, then male gender became directly associated
with TDR (64% bootstrap support), and with MSM and Belgian
origin (100% bootstrap support), whereas the association between
the two latter variables with TCs had lower bootstrap support
(31%).
Transmission Clusters
We identified 114 TCs, 16 of which harbored 32 of the 75 TDR
patients from our Leuven ND cohort. Five pairs and eight larger
clusters of $3 individuals were found among subtype B infected
patients, one cluster of 17 individuals with CRF02_AG, and one
pair for each subtypes C and CRF01_AE (see Table 2). Six of
these 16 TCs with TDR included only a single patient with TDR
whereas six clusters were TCs with TDR-OT and included 20
individuals from the Leuven ND cohort (26.7%, 20/75).
Singletons were frequently found in patients from the Leuven
ND cohort involved in TCs (81.3%, 26/32). Likewise, prevalence
against NRTI was the most frequent (81.3%, 26/32), followed by
PI (25.0%) and NNRTI (12.5%). Thymidine analogue mutations
(TAMs) were predominantly detected in TCs with TDR (81.3%,
26/32), mainly represented by the revertant at position 215
(59.4%, 19/32), followed by the mutations K219QR (18.8%),
L210W (15.6%) and M41L (6.3%). Mutations for NNRTI and PI
were I54V, N88D (each 15.6%), K103N (12.5%) and M46IL
(9.4%).
The characteristics of the Leuven ND cohort patients involved
in TCs were evaluated. Patients carrying TDR were significantly
more associated with TCs compared to patients without TDR
(OR: 1.95, see Table 1 and Table S1) and the association
remained when considering only larger clusters by excluding pairs
(OR: 2.86, 95% CI 1.59–5.01, p=,0.001). Similarly, when
including only TCs with TDR-OT, TDR remained significantly
Figure 1. Temporal trends and factors associated with transmitted drug resistance (TDR). (A) Trends of prevalence of TDR (percentage)
and the 95% confidence intervals (light shading) among newly diagnosed HIV-1 patients at ARC Leuven (Belgium) from 1998 to 2012 are shown for
the overall-TDR, NRTI-TDR, NNRTI-TDR, PI-TDR in blue, MSM overall-TDR and Belgian overall-TDR in red. (B) The significant variables associated with
TDR in the univariate analysis were included in the Bayesian network, the number next to the arcs represents the bootstrap support. Abbreviations:
NRTI: nucleoside reverse transcriptase inhibitors, NNRTI: non-nucleoside reverse transcriptase inhibitors, MSM: men who have sex with men, PI:
protease inhibitors.
doi:10.1371/journal.pone.0101738.g001
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associated with TCs (OR: 2.44, 95% CI 1.32–4.36, p = 0.002, see
Table S1). 32 out of 75 TDR patients were involved in TCs
(42.6%, 95% CI 32.1–53.9), while of the 703 patients without
TDR, only 194 were found in TCs (27.6%, 95% CI 24.4–31.0). As
expected, Leuven ND cohort patients with TDR and involved in
TCs were significantly more of Belgian origin (90.6% versus
65.5%; OR: 4.84, 95% CI 1.41–25.78, p = 0.005), infected with
subtype B (90.6% versus 63.9%; OR: 5.42, 95% CI 1.59–28.85,
p = 0.001) and characterized with MSM risk factor (78.1% versus
52.6%; OR: 2.71, 95% CI 1.07–7.84, p = 0.03) than their
counterparts without TDR (see Table S1). When we focussed on
predictors for TCs with TDR by including the data of controls,
subtype B remained significantly associated with TCs with TDR
(77.4% versus 65.1%, OR: 1.83 95% CI 1.03–3.35, p = 0.036).
However, TCs of patients with TDR were larger than TCs
without TDR (median 3.5 vs. 2 patients per TC, OR: 1.43 95%
CI 1.08–1.91, p = 0.001). Belgium as sampling country or as
country of origin and heterosexual contact were then more
frequent in the group of TCs that included solely patients without
evidence of TDR. Multivariate analysis did not show any
significant factor associated with patients in TCs with TDR versus
other TCs. Finally, we also performed separate analyses on TCs
with TDR-OT (see Table S1). The same variables remained
significantly associated with TCs in the univariate analysis, with
the exception of recent infection that became significant. The
median of the TCs with TDR-OT was larger than TCs without
TDR (5.5 versus 2 patients per TCs, OR: 2.01 (1.29–3.11).
Likewise, none of the variables were significant in the multivariate
analysis.
The characteristics of the Leuven TDR patients involved in
TCs are shown in Table 2. Five pairs included mainly naive MSM
originating from Belgium, infected with a subtype B strain carrying
one of the 215 revertants, whereas two pairs with subtype C and
CRF01_AE strains displaying mutations at PR position 46
included heterosexual Belgians with a foreign partner. Two large
subtype B TCs with TDR included 9 or more patients. Cluster
number 5 was composed of nine therapy-naive individuals
originating from Belgium with MSM as a risk factor and
diagnosed between 2007 and 2012. Seven of them displayed a
revertant at RT position 215 while two strains had no TDR.
Cluster number 13 (Figure 2B) included 26 naive patients mainly
from United Kingdom and countries of western and southern
Europe, western Asia and America. The main mode of
transmission was MSM infected with viruses carrying mutations
at position 219, except for six individuals who mainly originated
from Cyprus and did not display any mutations. The remaining
subtype B TCs were composed of three to six individuals. All had
at least one individual originating from Belgium and one from
another country. For instance, cluster number 1 included one
patient originating from Belgium and two patients from Russia
and Pakistan but infected in other countries like Finland and
Spain. One peculiar subtype B cluster with extensive NRTI and PI
resistance (cluster number 3) contained 6 therapy-naive MSM with
TDR all with a Belgian connection, either infected in Belgium or
originating from Belgium. On the other hand, the largest cluster of
non-B subtypes was composed of 17 individuals infected with
CRF02_AG and sampled in different countries from Central-
eastern Asia and Eastern Europe and characterized by different
risks factors including heterosexual orientation, intravenous drug
Figure 2. Examples of subtype B transmission clusters (TCs) with TDR: A maximum likelihood (ML) tree per subtype was
constructed, and TCs were confirmed by Bayesian Phylogenetic analyses. (A) The ML tree for subtype B (Leuven ND cohort and control
sequences) with the TCs colored in dark red. (B) The largest TC of subtype B: composed of therapy-naive patients, several nationalities and mutations
at RT position 219; bootstrap values above 98% are shown. Abbreviations: AR: Argentina, CY: Cyprus, GE: Germany, IT: Italy, UK: United Kingdom, USA:
United States of America, black diamond: men who have sex with men, asterisk: posterior distribution equal to 1 in the Bayesian phylogenetic
analysis.
doi:10.1371/journal.pone.0101738.g002
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user (IVDU) or vertical transmission. The resistance pattern was
also heterogeneous in this cluster. The majority of patients did not
display TDR mutations, whereas one naive patient sampled in
Belgium and originating from Kazakhstan displayed a mixture of
K219RK, and one patient who was tested in Russia was probably
treated and displayed high-level resistance against NRTI and
NNRTI.
Since the definition of clustering is still a matter of debate,
additional analyses were performed to assess the impact of the
genetic distance on the identification of TCs with values of 0.015,
0.03 and 0.045. As a result, the number of TCs with TDR
decreased to 9, 13 and 17, respectively, including 22.7%, 29.3%
and 36.0% of the 75 patients with TDR. The number of TCs that
included TDR patients was larger with the genetic distance 0.045
because the cluster with 9 individuals identified as number 5 in
Table 2 was split in one pair (ARCL-16-TDR and ARCL-18-
TDR) and one cluster with the remaining patients. With the
stringent criteria of 0.015, TDR was still associated with TCs (OR:
2.56 05% CI 1.32–4.76, p= 0.003). Subtype B infection remained
as the factor associated with TCs with TDR (p= 0.002), whereas
sociodemographic factors such as Belgian nationality and MSM
contact were not significantly linked.
Potential Impact Of TDR On First-Line Regimen
For each patient with TDR, we analysed the genotypic
susceptibility score (GSS) of the three regimens most frequently
prescribed during the year the patient was diagnosed, and for each
patient who in the meantime had started treatment we also
estimated the GSS of the first-line therapy received. Rega
algorithm 9.1.0 was used for these analyses, which has a
recommended GSS for patients with TDR. This recommendation
was introduced in March 2007 and suggests a regimen with GSS
of$3.5 when TDR is detected, thereby suggesting a triple therapy
with a fully active boosted PI which receives a score 1.5, but not
with an NNRTI which receives a score of 1 when fully active.
Amongst the 636 patients who started ART, the GSS of the
actual prescribed first-line regimen was $3.5 in 261 patients
(41.0%), 3 in 357 patients (56.1%), and ,3 in 18 patients (2.8%).
The latter group included five patients without TDR, of which
three patients were treated with bi-therapy in 1998, one with bi-
therapy including a PI in 2002 and one with a mono PI regimen in
2010. Although the demographic characteristics were similar
between the patients with a GSS $3 and ,3, the latter group
more often started ART before 2002 (8/18, p,0.001).
In the group of patients with viruses carrying TDR, 60 started
therapy before the end of 2012. The GSS was $3.5 in 34 patients
(56.7%), equal to 3 in 13 patients (21.7%), and ,3 in 13 patients
(21.7%). The latter group displayed resistance only to NRTIs (6/
13), only to PI (2/13) or dual resistance (5/13).
Sustained undetectable viral load during the first-line therapy
was reached in 83.3% (50/60) of the TDR patients, whereas 3.3%
of the patients (2/60) had sustained low level viremia without
evidence of virological rebound above 500 copies/ml. Four
patients (6.7%) had early changes in ART due to toxicity and 1
patient (1.7%) died shortly after therapy initiation. Only 5.1% of
the patients (3/60) displayed virological failure and the emergence
of major NNRTI resistance-related mutations. Two of these
patients displayed evidence of only NRTI TDR mutations at
baseline and received a NRTI+NNRTI regimen with a GSS equal
to 3. The third patient started a NRTI+NNRTI therapy with a
GSS equal to 1 in 2004, two days after the first contact date and
two weeks before the drug resistance results were available. In this
patient, the therapy was quickly changed after receiving the
baseline drug resistance report indicating NRTI and NNRTI
TDR mutations and observing no virological response. Subse-
quent drug resistance testing on a later sample revealed further
accumulation of NNRTI resistance.
To appreciate the value of baseline drug resistance testing, the
GSS was calculated for the three most frequently prescribed first-
line regimens in patients displaying TDR in our cohort per year
(see Table S2). Theoretically, 49.3% of TDR patients (37/75) were
likely to receive a potential suboptimal regimen (GSS,3) if
baseline drug resistance testing had not been available to the
treating physician. However, the frequency of these patients is
decreasing over time (p = 0.002). Up until 2003, the most common
first-line regimens included a thymidine analogue with either a
NNRTI- or unboosted PI. Thereafter, tenofovir or abacavir were
more commonly used as supporting NRTI, but a GSS,3 was still
mainly observed for NRTI+NNRTI regimens. A low GSS under a
boosted PI based regimen would only have accounted for
approximately 15% of the TDR cases per year between 2005
and 2011.
Discussion
The TDR surveillance in the 778 included patients who were
newly diagnosed with HIV-1 at our clinic in Leuven showed a
stable overall prevalence of 9.6% between 1998 and 2012. This
result is in line with the 9.5% of the latest national survey that
included 285 patients who were newly diagnosed in Belgium
between 2003 and 2006 [11]. It was also consistent with the stable
overall TDR levels of 9.7% in Spain and of 9.0% in France, results
from national surveys with a similar design and time frame as our
study [34,39], and with the overall trend of 8.9% in Europe
between 2002 and 2007 [26,40]. However, the overall TDR in our
local epidemic was higher than the 5.6% between 2003 and 2010
in Sweden [5] and the 6.5% between 2001 and 2009 in Ghent
(Belgium) [4]. These regional differences highlight the importance
of studying local epidemics and suggest that TDR prevalence may
vary within a single country. Indeed, our findings may not be
generalizable to the HIV-1 epidemic in Belgium because our
cohort has a higher prevalence of MSM and of individuals
originating from Belgium. It should be pointed out, however, that
the demographic characteristics data of our study population was
more complete than the national database for which nationality
and mode of transmission were not available in approximately
25% of the cases. Although our study could have overestimated
the level of TDR, due to patients who were unwilling to disclose
their ART status, measures were taken to decrease the number of
misclassifications. Patient records were exhaustively revised by
clinicians and virologists, and individuals with evidence of drug
resistance and viral load profiles suggestive of treatment were not
considered drug naive.
While subtype B, being MSM, male gender, originating from
Belgium, recently infected, and involvement in TCs were all
significant predictors for TDR, only subtype B remained
significantly associated in the multivariate analysis. Bayesian
analyses however, showed the dependency of this factor on being
of Belgian origin and MSM. Similarly when subtype B was
excluded, male gender became directly associated with TDR with
low support but significantly dependent on Belgian origin and
MSM. These findings are in agreement with previous reports from
other Belgian, European and American studies [4,5,11,39,41]. In
a recent study, the association of subtype with country of sampling,
risk group and gender has been interpreted as evidence for highly
compartmentalized epidemics in Europe [42]. Therefore, the early
introduction of subtype B in European MSM and their broad
access to HIV care and ART for decades might explain the single
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direct association of subtype B with TDR in many resource-rich
settings. Nevertheless, recent studies revealed an increasing
prevalence of TDR among Sub-Saharan African migrants residing
in Spain and Sweden, potentially linked to the increasing drug
resistance levels in Africa [5,43]. However in our cohort, Sub-
Saharan African patients were still associated with less TDR and
we did not observe a time trend in those patients (data not shown).
Fluctuations in TDR levels were observed over the entire study
period, but the only significant trend was a parabolic trend
detected for transmitted NNRTI resistance. The overall NNRTI
TDR prevalence was 2.2%, with a maximum of 6.5% in 2008-
2009. This parabolic trend, mainly linked to the detection of
K103N and to a Belgian origin, was not observed among recently
infected patients. Although a parabolic trend with a peak in 2004
was also described in the SPREAD study that included data up
until 2005 [26], the same surveillance up to 2007 showed a linear
increase over time [40] potentially associated with the frequent use
of NNRTI in first-line regimens as the authors suggested.
Similarly, the local change of prescribing practices to more potent
regimens in later years, use of drug resistance testing and the
longer time period analyzed in this study could explain the
parabolic trend. In the total cohort, TDR associated with NRTI
and PI resistance fluctuated around 6.5% and 2.2%, respectively.
Among recently infected patients, NRTI- and PI-TDR levels
increased to 12.4% and 6.7% respectively. This increase was not
observed for NNRTI resistance, presumably due to the lower
impact of NNRTI mutations on viral fitness with consequently a
lower likelihood of reversion to wild-type and of a TDR
underestimation by population-based Sanger sequencing in
chronically infected patients.
Singletons were predominantly detected in our cohort, with
TAMs as the most commonly observed. Although the use of
zidovudine has decreased over the last few years, we did not find
any time trend for TAMs. The peak in NNRTI TDR in 2008 was
not related to clustered transmission of TDR or migration from
other countries as has been suggested in other settings [12,43].
However, it might have been linked with the enhanced use of
NNRTI-containing combinations in the years before. From 2009
onwards, the most commonly prescribed regimen was the potent
combination tenofovir+emtricitabine+efavirenz. Up until 2012, no
other available NNRTI- or PI/ritonavir-based regimen had
proven superior to this regimen with respect to virologic responses.
If resistance testing had not been performed and patients with
TDR would have received one of the preferred first-line regimens
at that time, approximately half of them would likely have received
a regimen in which the virus had lost susceptibility to at least one
of the prescribed drugs. Irrespective of the detected TDR by
population-based Sanger sequencing, all of them would have had
a higher risk of virological failure, as NNRTI-based regimes were
commonly prescribed from 2002 onwards [8]. However, 83% of
the patients with TDR and who started ART achieved undetect-
able viral load thanks to the prescription of potent regimens
enabled by the availability of drug resistance results. Only 3
patients with baseline resistance to NRTI had virological failure
with development of NNRTI resistance after the initiation of a
NRTI+NNRTI regimen.
In this cohort, 42.6% of the TDR patients were involved in
TCs, which included nine clusters and seven pairs. Because we
were interested in observing TCs over a period of 15 years, a
genetic distance of 0.06 substitutions per site and a bootstrap
support of $98% were used to define TCs. These TCs were also
confirmed using Bayesian phylogenetic techniques, indicating that
the obtained results were robust [4,7,34]. Although, the compar-
ison between studies of transmission networks is difficult due to the
differences in sampling, phylogenetic techniques and the lack of a
standardized TC definition, our results were in line with a study
carried out in Ghent (Belgium) in which 18 out of 33 (55%) TDR
patients were involved in pairs or larger clusters [4]. When a more
stringent criterion of 0.015 genetic distance was used, the
percentage of TDR patients involved in TCs decreased to
approximately 23%. In general, some conclusions can be drawn
from the TCs analyses. First, none of the factors were significantly
associated with TCs with TDR in the multivariate model,
although a dependency between subtype B and clustering was
found in the Bayesian network and TDR was significantly
associated with TCs in the univariate analysis. Therefore we were
unable to identify a non-sequence based predictor of being in TCs
with TDR, even though the odds were higher for patients who
were MSM and originating from Belgium. This result is similar to
other studies performed in Europe [4,34]. Second, TAMs were
more frequently found in TCs and this was also observed in the
Ghent cohort and other settings [3,4,7]. Third, TCs with TDR
involved mainly therapy-naive individuals, chronically or recently
infected, rather than ART-experienced patients, which could
suggest that drug naive people, potentially unaware of their HIV
seropositive status, are the main source of TDR instead of patients
failing ART [3,6,7]. Fourth, 7 out of 16 TCs with TDR involved
patients of different nationalities. Although, we were not able to
retrace the country of infection in many instances, this may imply
that migration plays an important role in the local spread of
subtype B as previously described [44], but also of TDR. Fifth,
spread of non-B subtypes in the local epidemic was still limited and
was related with heterosexuals as has been described in other
epidemics [6]. They were also not prone to spread TDR. They
often involved Belgians and other nationalities that could imply a
limited intermixing of the HIV-1 epidemic between locals and
immigrants.
Although we used all the sequences available in public databases
and from a collaborative European dataset, for 7 TCs with TDR
we did not find evidence that patients other than the ones followed
at our clinic were involved in transmission networks. Similarly, 6
TCs with TDR patients from the Leuven ND cohort included only
a single patient with TDR, and for these patients, no evidence of
onward transmission of TDR is available. When 3 or more
patients in a TC had the same TDR mutation profile, we indicated
the cluster as TDR-OT, since this is suggestive of onward
transmission of TDR, although we cannot exclude that all these
TDR patients received their resistance from a treated patient. The
association between TDR and TCs remained, also for those TCs
with TDR-OT. Since 27% of the patients from the Leuven ND
cohort were involved in those TCs, this could imply an important
role of local transmission on the spread of TDR. Nevertheless, we
cannot exclude the possibility that the networks might include
other intermediary individuals who were not sampled or unaware
of their seropositive status, known limitations of phylogenetic
analyses.
Singletons and the TAM 215 were predominant in TCs, but the
clinical impact on the current first-line therapies remains limited.
However, two TCs that involved MSM individuals originating
from Belgium with viruses carrying the K103N were detected. The
latest diagnosis date was 2009 in these TCs, suggesting that in our
local epidemic this mutation was not involved in a recent spread in
contrast to a reported outbreak in Namur (Belgium) [12].
Continuous monitoring of the spread of this mutation is required
to establish the impact on current practices. On the other hand,
two large clusters were detected with the TAM 219 and they
involved different nationalities from Europe, Asia and America.
One of these TCs contained one patient living in Belgium but
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originating from Kazakhstan, and control sequences from
Uzbekistan that were part of an outbreak of CRF02_AG among
IVDU [45]. Our analyses revealed the involvement of other
countries and risk groups and the absence of K219R in many of
the clustered sequences. The other large cluster included MSM
individuals infected with subtype B and control sequences mainly
from United Kingdom [46] and other countries in Europe. The
majority of strains in this cluster displayed K219Q with only a few
strains displaying K219R or no TDR.
In summary, this study showed a stable trend of almost 10%
overall TDR between 1998 and 2012 in our Leuven (Belgium)
cohort. TDR associated with NNRTI resistance displayed a
parabolic trend that overlapped with an up-and-down NNRTI
TDR trend in Belgians and with the trend of K103N. Our cohort
was mainly composed of chronically infected patients and around
43% of the patients with TDR were involved in transmission
networks, suggesting public health policies that target early
diagnoses of recently infected patients are needed. Although the
main factor related with TDR was subtype B, this variable was
dependent on Belgian nationality and MSM mode of transmission.
While these variables were also associated with being in TCs with
TDR, we were unable to significantly identify a population that
could be targeted for future TDR prevention policies. More local,
national and international surveillance studies are needed to
confirm the significance and durability of our observations, as
changes in TDR levels and patterns are not straightforward to
predict due to potential changes in prevention, testing and
treatment strategies and changes in other potentially important
drivers, such as e.g. behaviour and migration.
Supporting Information
Table S1 Characteristics of patients from the Leuven
ND cohort and from patients involved in transmission
clusters. Transmission clusters with likely onward transmission
included clusters number 2, 3, 5, 6, 7, 13 in Table 2. Multivariate
analysis was not significant in any of the analyses. Abbreviations:
CI confidence intervals, IVDU intravenous drug user, MSM men
who have sex with men, n sample, OR odds ratio, % percentage
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Table S2 Impact of transmitted drug resistance (TDR)
on clinical care: The genotypic susceptibility score (GSS)
of each sequence with TDR was calculated for the
antiretroviral regimens most frequently prescribed in
the year of diagnosis (top three). For instance, the GSS was
less than 3 for each of the most frequently prescribed regimens in
the only sequence with TDR sampled in 1998. According to the
Rega algorithm, a GSS of at least 3.5 is advised for the first-line
therapy in a patient carrying a virus with TDR. Abbreviations:
ART antiretroviral therapy, 3TC lamivudine, ABC abacavir,
ATV atazanavir, ATV/r ritonavir-boosted atazanavir, AZT
zidovudine, D4T stavudine, DDI didanosine, DRV/r ritonavir-
boosted darunavir, EFV efavirenz, FPV/r ritonavir-boosted
fosamprenavir, FTC emtricitabine, IDV indinavir, LPV/r ritona-
vir-boosted lopinavir, NFV nelfinavir, NVP nevirapine, TDF
tenofovir disoproxil fumarate.
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